When medical cannabis was legalised in the UK in November 2018, it was heralded as a turning point. Nearly eight years on, the system remains fractured. Fewer than five NHS prescriptions are issued each month, private clinics charge fees that put treatment out of reach for many, and the licensing framework that governs cultivation, import, and distribution has drawn criticism from every corner of the sector. The Home Office's 2026 licensing review, launched in April, represents the most significant regulatory intervention since legalisation itself.
What the review covers
The review's terms of reference are broad. They encompass cultivation licences, import and export controls, pharmacy distribution, and the security requirements that private clinics and producers must meet. At the heart of the review is a question that has dogged the UK medical cannabis programme since its inception: why has a legal market produced so few legally prescribed products?
The answer, according to patient groups, clinicians, and industry bodies, lies in a licensing regime designed for illicit drug control rather than medical supply. Schedule 2 licensing — which governs the production and distribution of controlled substances — was built for opioids and synthetic pharmaceuticals. Cannabis, a plant-based medicine with dozens of active compounds, does not fit neatly into a framework designed for single-molecule drugs. The review aims to address this mismatch.
The cultivation bottleneck
One of the most contentious issues is domestic cultivation. The UK currently imports nearly all of its medical cannabis from Canada, the Netherlands, and Portugal. This dependency drives up costs, introduces supply chain vulnerabilities, and limits the range of products available to patients. British Sugar's Wissington facility, which cultivates cannabis for GW Pharmaceuticals' Epidyolex, remains the only large-scale domestic production site operating under a Home Office licence.
The review is considering a tiered licensing system that would separate medical cannabis cultivation from the broader controlled drug licensing regime. This could lower the barrier to entry for domestic producers, increase competition, and reduce costs for patients. Industry sources suggest that a tiered approach — with different security and compliance requirements for different scales of operation — could unlock investment in UK-based cultivation that has long been deterred by prohibitive licensing costs.
What this means for patients
For patients, the stakes are straightforward. The current system prices medical cannabis out of reach for most. A typical private prescription costs between £150 and £500 per month, with initial consultation fees adding £100 to £250 on top. NHS prescriptions remain vanishingly rare, largely because NICE guidance does not recommend cannabis-based medicines for most conditions, and specialist doctors — the only clinicians permitted to prescribe — are concentrated in a handful of private clinics.
The review could change this dynamic by streamlining the licensing of pharmacies to dispense medical cannabis. At present, only a small number of specialist pharmacies are licensed to handle Schedule 2 controlled drugs, creating distribution bottlenecks that limit patient access. A revised framework could expand the number of dispensing pharmacies, making it easier for patients to collect prescriptions locally rather than relying on mail-order services.
The political dimension
The review is not without political risk. Cannabis remains a sensitive topic in Westminster, and any move perceived as liberalising drug policy will face opposition from conservative MPs and sections of the press. The Home Office has been careful to frame the review as a technical exercise focused on improving the medical supply chain, not as a step towards recreational legalisation.
This framing is both pragmatic and limiting. It allows the review to proceed without triggering a broader political debate, but it also means that some of the structural barriers to access — NICE guidance, specialist-only prescribing, and the Schedule 2 classification itself — are off the table. Patient advocates have criticised this narrow scope, arguing that licensing reform alone cannot fix a system where the fundamental problem is that the NHS will not prescribe.
Timeline and expectations
The review is expected to publish its interim findings in September 2026, with final recommendations due by the end of the year. Any legislative changes would follow in 2027 at the earliest. For patients currently paying hundreds of pounds per month for private prescriptions, that timeline offers little immediate relief.
However, the review represents the first serious attempt to address the structural failures of the UK medical cannabis programme. If it leads to a more rational licensing framework — one that treats cannabis as a medicine rather than a controlled substance requiring extraordinary security measures — it could mark the beginning of a more accessible, more affordable, and more equitable system. For the estimated 1.4 million UK medical cannabis patients currently self-medicating through the illicit market, that change cannot come soon enough.
What to watch
Patients and advocates should watch for three key indicators in the coming months. First, whether the interim report recommends a tiered licensing system. Second, whether it addresses the pharmacy distribution bottleneck. And third, whether the Home Office signals any willingness to revisit the prescribing restrictions that keep NHS doctors from recommending cannabis-based medicines. The licensing review may be technical in scope, but its implications for patient access are profound.
